Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018

The US Food and Drug Administration (FDA) regulates high-risk medical devices through the premarket approval (PMA) pathway, which requires clinical evidence assuring safety and effectiveness for approval.[1][1] After approval, manufacturers may face barriers to successful commercialization, such as